FR17C1011I2 - Inhibiteurs de proteasomes - Google Patents

Inhibiteurs de proteasomes

Info

Publication number
FR17C1011I2
FR17C1011I2 FR17C1011C FR17C1011C FR17C1011I2 FR 17C1011 I2 FR17C1011 I2 FR 17C1011I2 FR 17C1011 C FR17C1011 C FR 17C1011C FR 17C1011 C FR17C1011 C FR 17C1011C FR 17C1011 I2 FR17C1011 I2 FR 17C1011I2
Authority
FR
France
Prior art keywords
proteasome inhibitors
proteasome
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR17C1011C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38691782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR17C1011(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of FR17C1011I1 publication Critical patent/FR17C1011I1/fr
Application granted granted Critical
Publication of FR17C1011I2 publication Critical patent/FR17C1011I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR17C1011C 2007-08-06 2017-04-14 Inhibiteurs de proteasomes Active FR17C1011I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/017440 WO2009020448A1 (en) 2007-08-06 2007-08-06 Proteasome inhibitors

Publications (2)

Publication Number Publication Date
FR17C1011I1 FR17C1011I1 (hr) 2017-05-26
FR17C1011I2 true FR17C1011I2 (fr) 2018-04-27

Family

ID=38691782

Family Applications (1)

Application Number Title Priority Date Filing Date
FR17C1011C Active FR17C1011I2 (fr) 2007-08-06 2017-04-14 Inhibiteurs de proteasomes

Country Status (33)

Country Link
EP (3) EP2527347A1 (hr)
JP (1) JP5261488B2 (hr)
KR (6) KR20140042932A (hr)
CN (1) CN101772507B (hr)
AU (1) AU2007357338B2 (hr)
BR (1) BRPI0721905B8 (hr)
CA (1) CA2695082C (hr)
CY (2) CY1113386T1 (hr)
DK (1) DK2178888T3 (hr)
EA (1) EA028622B1 (hr)
EC (1) ECSP10010015A (hr)
ES (1) ES2390606T3 (hr)
FR (1) FR17C1011I2 (hr)
GE (1) GEP20125599B (hr)
HK (2) HK1143595A1 (hr)
HR (1) HRP20120745T1 (hr)
HU (1) HUS1700018I1 (hr)
IL (4) IL203641A (hr)
LT (1) LTC2178888I2 (hr)
LU (1) LUC00013I2 (hr)
MY (1) MY161991A (hr)
NL (1) NL300871I2 (hr)
NZ (1) NZ582693A (hr)
PH (1) PH12014500053B1 (hr)
PL (1) PL2178888T3 (hr)
PT (1) PT2178888E (hr)
RS (1) RS52435B (hr)
SG (1) SG10201508712QA (hr)
SI (1) SI2178888T1 (hr)
TN (1) TN2010000060A1 (hr)
UA (1) UA97536C2 (hr)
WO (1) WO2009020448A1 (hr)
ZA (1) ZA201000348B (hr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
PT1948678E (pt) 2005-11-09 2013-07-16 Onyx Therapeutics Inc Compostos para inibição de enzimas
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
ES2578905T5 (es) 2007-10-04 2020-03-18 Onyx Therapeutics Inc Inhibidores de proteasa epoxi cetona peptídicos cristalinos y la síntesis de ceto-epóxidos de aminoácidos
GEP201706703B (en) 2008-06-17 2017-07-25 Millennium Pharmaceuticals Inc (A Delaware Corporation) Boronate ester compounds and pharmaceutical compositions thereof
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
AP2011005690A0 (en) 2008-10-21 2011-06-30 Onyx Therapeutics Inc Combination therapy with peptide epoxyketones.
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
CN102725300B (zh) 2009-12-22 2015-03-11 赛福伦公司 蛋白酶体抑制剂及其制备、纯化、和应用的方法
MA34133B1 (fr) 2010-03-01 2013-04-03 Onyx Therapeutics Inc Composes pour inhibiteurs de l'immunoproteasome
US8513218B2 (en) 2010-03-31 2013-08-20 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
WO2012177835A1 (en) * 2011-06-22 2012-12-27 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
HUE060305T2 (hu) * 2011-08-30 2023-02-28 Tufts College FAP-aktivált proteaszóma inhibitorok a szolid tumorok kezelésére
SG11201403254QA (en) * 2011-12-22 2014-07-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
CA2862320A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Method of treatment of nasopharyngeal cancer
US20160008382A1 (en) * 2012-01-24 2016-01-14 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
CN109180780B (zh) * 2012-07-26 2022-03-18 圣特莱国际公司 多肽环氧酮化合物
JP2013006855A (ja) * 2012-09-03 2013-01-10 Millennium Pharmaceuticals Inc プロテアソーム阻害剤
ES2615744T3 (es) * 2012-12-03 2017-06-08 F. Hoffmann-La Roche Ag Compuestos de ácido triazol-borónico sustituidos
EA201690686A1 (ru) * 2013-10-03 2016-08-31 Милленниум Фармасьютикалз, Инк. Способ профилактики или лечения системной красной волчанки и/или волчаночного нефрита
MA39964A (fr) 2014-05-20 2015-11-26 Millennium Pharm Inc Inhibiteurs du protéasome contenant du bore destinés à être utilisés après une thérapie contre le cancer primaire
EP3808349B1 (en) 2014-08-07 2022-10-05 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
MA41555A (fr) * 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
US10144761B2 (en) 2015-06-19 2018-12-04 Hanlin Scientific Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
CN106608883A (zh) * 2015-10-21 2017-05-03 北京大学 蛋白酶体抑制剂mln9708的合成方法
WO2017198194A1 (zh) * 2016-05-19 2017-11-23 成都奥璟生物科技有限公司 一种硼酸和硼酸酯类化合物及其应用
CN106008572B (zh) * 2016-05-23 2018-08-17 成都千禧莱医药科技有限公司 一类二肽硼酸化合物及制备方法和用途
KR102595723B1 (ko) 2016-06-21 2023-10-27 오리온 옵탈몰로지 엘엘씨 헤테로시클릭 프롤린아미드 유도체
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
US10995103B2 (en) 2016-07-25 2021-05-04 Shenzhen Targetrx, Inc. Substituted boric acid compound, pharmaceutical composition comprising same, and application thereof
TW201831191A (zh) * 2017-01-23 2018-09-01 大陸商成都奥璟生物科技有限公司 一種新的硼酸衍生物及其藥物組合物
WO2018160717A1 (en) 2017-02-28 2018-09-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
CN108794516A (zh) * 2017-04-26 2018-11-13 上海时莱生物技术有限公司 硼酸和硼酸酯类化合物及其制备方法和用途
CN109305980B (zh) * 2017-07-28 2022-10-11 成都奥璟生物科技有限公司 一种硼酸酯化合物、其合成方法及其用途
EP3672978B1 (en) 2017-08-25 2021-10-06 Synthon B.V. Process for making ixazomib and its intermediates
JP2018024694A (ja) * 2017-10-03 2018-02-15 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
CN110903310B (zh) * 2018-09-14 2022-11-22 成都奥璟生物科技有限公司 一种硼酸酯类药物及其用途
CN110357787A (zh) * 2019-08-02 2019-10-22 苏州艾和医药科技有限公司 依沙佐米合成工艺研究
US20220362268A1 (en) * 2019-10-07 2022-11-17 Cornell University Antimicrobial and antiviral effects of c2-c7 alkyl boronic acids
CN110950897B (zh) * 2019-12-12 2021-05-28 山东大学 一种组蛋白去乙酰化酶、蛋白酶体双靶点抑制剂及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
EP1355910B1 (en) * 2001-01-25 2011-03-09 The United States of America, represented by the Secretary, Department of Health and Human Services Formulation of boronic acid compounds
US6933290B2 (en) 2001-05-30 2005-08-23 Novartis Ag 2-{N-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
UA88771C2 (ru) * 2003-08-14 2009-11-25 Сефалон, Инк. Ингибиторы протеасомы и способ их применения (варианты)
EP2377868A1 (en) * 2004-03-30 2011-10-19 Millennium Pharmaceuticals, Inc. Synthesis of Bortezomib
WO2006008660A2 (en) 2004-07-20 2006-01-26 Affinium Pharmaceuticals, Inc. Streptococcus pneumoniae enoyl- (acyl-carrier-protein) reductase (fabk)
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
GB0513349D0 (en) 2005-06-29 2005-08-03 Torres Manel Non-woven fabric
EP1898899A4 (en) 2005-07-05 2009-07-29 Tufts College ALPHA PROTEIN INHIBITORS FOR FIBROBLAST ACTIVATION

Also Published As

Publication number Publication date
EP2527347A1 (en) 2012-11-28
IL242292A (en) 2017-12-31
HUS1700018I1 (hu) 2017-05-29
UA97536C2 (en) 2012-02-27
CN101772507B (zh) 2012-12-12
CA2695082A1 (en) 2009-02-12
WO2009020448A1 (en) 2009-02-12
TN2010000060A1 (en) 2011-09-26
ZA201000348B (en) 2011-03-30
NL300871I2 (nl) 2017-12-07
FR17C1011I1 (hr) 2017-05-26
ECSP10010015A (es) 2010-04-30
NZ582693A (en) 2012-01-12
CY1113386T1 (el) 2016-06-22
AU2007357338A1 (en) 2009-02-12
CY2017016I2 (el) 2017-07-12
SG10201508712QA (en) 2015-11-27
IL242291A (en) 2017-12-31
PH12014500053A1 (en) 2015-03-30
AU2007357338B2 (en) 2014-03-20
CN101772507A (zh) 2010-07-07
EP2178888B1 (en) 2012-07-04
KR101474831B1 (ko) 2014-12-19
JP2010535759A (ja) 2010-11-25
CA2695082C (en) 2015-07-28
MY161991A (en) 2017-05-31
KR101831674B1 (ko) 2018-02-23
SI2178888T1 (sl) 2012-11-30
BRPI0721905B8 (pt) 2021-05-25
PT2178888E (pt) 2012-10-04
IL242290A0 (en) 2015-11-30
CY2017016I1 (el) 2017-07-12
KR20170004031A (ko) 2017-01-10
JP5261488B2 (ja) 2013-08-14
DK2178888T3 (da) 2012-10-01
LUC00013I1 (hr) 2017-04-06
KR20150010802A (ko) 2015-01-28
BRPI0721905A2 (pt) 2014-02-25
HRP20120745T1 (hr) 2012-10-31
IL242290A (en) 2017-12-31
PL2178888T3 (pl) 2012-11-30
EP2178888A1 (en) 2010-04-28
HK1143595A1 (en) 2011-01-07
IL242292A0 (en) 2015-11-30
EA028622B1 (ru) 2017-12-29
KR20100059811A (ko) 2010-06-04
BRPI0721905B1 (pt) 2020-11-17
ES2390606T3 (es) 2012-11-14
LUC00013I2 (hr) 2017-06-19
IL203641A (en) 2015-11-30
GEP20125599B (en) 2012-08-10
IL242291A0 (en) 2015-11-30
KR20140042932A (ko) 2014-04-07
KR20140042933A (ko) 2014-04-07
RS52435B (en) 2013-02-28
KR20160040735A (ko) 2016-04-14
PH12014500053B1 (en) 2015-03-30
LTC2178888I2 (lt) 2018-03-12
EP3210987A1 (en) 2017-08-30
LTPA2017010I1 (lt) 2017-05-10
HK1182924A1 (zh) 2013-12-13
EA201070247A1 (ru) 2010-06-30

Similar Documents

Publication Publication Date Title
FR17C1011I2 (fr) Inhibiteurs de proteasomes
CY2020024I2 (el) Αναστολεiς βητα-λακταμασων
BRPI0807547A2 (pt) Inibidores de aspartil protease hetercíclicos
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
BRPI0810365A2 (pt) Inibidores de mlc-1 de indol 7-substituído
IT1394247B1 (it) Dispositivo di serraggio
BRPI0814797A2 (pt) Inibidores dna-pk
BRPI0807772A2 (pt) Dispositivo de embalar
BRPI0918564A2 (pt) inibidores
BRPI0912234A2 (pt) derivados de salinosporamida como inibidores de proteassomas
FI20085565A (fi) Tiivistyslaite
AT506380A3 (de) Stempelvorrichtung
DE602009001221D1 (de) Abdichtungsvorrichtung
DK2066662T3 (da) Serinhydrolaseinhibitorer
BRPI0918966A2 (pt) inibidores de protease
NO20070960A (no) Teine
BRPI0919073A2 (pt) inibidores de protease
GB0707315D0 (en) Novel proteasome inhibitor
FI20075320A0 (fi) Uusia käyttökelpoisia inhibiittoreita
ITMI20061754A1 (it) Dispositivo di smussatura perfezionato